Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 847 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapse/Refractory Multiple Myeloma Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
carfilzomib, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
RAD001, Sorafenib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Daratumumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
33
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
Drug
Lead sponsor
Benjamin T Diamond, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CEP-18770
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Selinexor, Ruxolitinib, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced May 21, 2026, 6:18 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Dexamethasone, Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Palm Springs, California • Riverside, California • Glenwood Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Mezigdomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • New Haven, Connecticut • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
suramin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced May 21, 2026, 6:18 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Interventions
MK-4002
Drug
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 21, 2026, 6:18 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Relapse/Refractory Multiple Myeloma
Interventions
CYAD-211, Endoxan, Fludara
Biological · Drug
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Lenalomide, Talquetamab
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis, Pomalidomide
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dasatinib, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Interventions
OriCAR-017
Drug
Lead sponsor
OriCell Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ciforadenant, daratumumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone, Bortezomib
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
Tampa, Florida • Westwood, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
N-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced May 21, 2026, 6:18 PM EDT